西洛他唑杂质 I
英文名称 | Cilostazol Impurity I |
CAS | 73963-62-9 |
储存条件 | RT |
单位 | 瓶 |
规格 | 20mg |
西洛他唑杂质 I
英文名称 | Cilostazol Impurity I |
CAS | 73963-62-9 |
储存条件 | RT |
单位 | 瓶 |
规格 | 20mg |
西洛他唑 标准品
英文名称 | Cilostazol |
CAS | 73963-72-1 |
分子式 | C20H27N5O2 |
分子量 | 369.46 |
储存条件 | 2-8℃ |
规格 | 100mg |
西洛他唑
MDL | MFCD00866780 |
EC | EINECS 689-122-9 |
InChIKey | RRGUKTPIGVIEKM-UHFFFAOYSA-N |
InChI | InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26) |
PubChem CID | 2754 |
别名 | OPC 21; OPC 13013 |
英文名称 | Cilostazol |
CAS | 73963-72-1 |
分子式 | C20H27N5O2 |
分子量 | 369.46 |
纯度 | ≥99% |
单位 | 瓶 |
生物活性 | Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1-2]. |
IC50 | 0.2 μM ( PDE 3A)[1] |
In Vitro | Cilostazol selectively inhibits cGMP-inhibited phosphodiesterase (PDE 3) and is a potent inhibitor of platelet aggregation induced by various agonists.Cilostazol inhibits stress-induced human platelet aggregation (SIPA) dose-dependently, with an IC50 of 15 μM for SIPA, and with a similar IC50 of 12.5 μM for ADP-induced platelet aggregation[2]. Cilostazol directly and effectively inhibits the activation of HSC but not of Kupffer cells[3]. |
In Vivo | ilostazol (clinically used doses; p.o.; for 2 weeks) could alleviate CCl4 -induced hepatic fibrogenesis in vivo, presumably due to its direct effect to suppress HSC activation[3]. |
SMILES | O=C1NC2=C(C=C(OCCCCC3=NN=NN3C4CCCCC4)C=C2)CC1 |
靶点 | Phosphodiesterase (PDE) |
数据来源文献 | [1]. Schr?r K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9.
[2]. Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61(25):PL 383-9. [3]. Saito S, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res. 2013 Apr 19. |
规格 | 10mg 50mg 100mg |
是一种有效的选择性磷酸二酯酶3型抑制剂(PDE3)。它也是腺苷摄取抑制剂。
Cilostamide;西洛酰胺
有效期 | 2年 |
InChIKey | UIAYVIIHMORPSJ-UHFFFAOYSA-N |
InChI | InChI=1S/C20H26N2O3/c1-22(16-6-3-2-4-7-16)20(24)8-5-13-25-17-10-11-18-15(14-17)9-12-19(23)21-18/h9-12,14,16H,2-8,13H2,1H3,(H,21,23) |
PubChem CID | 2753 |
别名 | 斯台酰胺;OPC-3689 |
CAS | 68550-75-4 |
分子式 | C20H26N2O3 |
分子量 | 342.43 |
储存条件 | 2-8℃ |
纯度 | ≥98% |
外观(性状) | Off-white Solid |
单位 | 瓶 |
SMILES | O=C(N(C1CCCCC1)C)CCCOC2=CC3=C(NC(C=C3)=O)C=C2 |
靶点 | Phosphodiesterase (PDE) |
规格 | 5mg 10mg |